Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CELC |
---|---|---|
09:32 ET | 650 | 16.65 |
09:39 ET | 500 | 16.51 |
09:41 ET | 100 | 16.5 |
09:43 ET | 1400 | 16.5 |
09:45 ET | 4000 | 16.475 |
09:52 ET | 300 | 16.52 |
09:54 ET | 11739 | 16.515 |
09:56 ET | 4100 | 16.5 |
09:57 ET | 1000 | 16.51 |
09:59 ET | 1325 | 16.435 |
10:01 ET | 200 | 16.3 |
10:03 ET | 5200 | 16.42 |
10:06 ET | 1530 | 16.345 |
10:08 ET | 100 | 16.26 |
10:12 ET | 500 | 16.17 |
10:14 ET | 200 | 16.22 |
10:15 ET | 4218 | 16.33 |
10:19 ET | 100 | 16.39 |
10:28 ET | 300 | 16.45 |
10:32 ET | 480 | 16.433 |
10:33 ET | 100 | 16.43 |
10:35 ET | 959 | 16.47 |
10:39 ET | 100 | 16.475 |
10:44 ET | 100 | 16.45 |
10:46 ET | 195 | 16.5 |
10:48 ET | 100 | 16.31 |
10:50 ET | 200 | 16.39 |
10:53 ET | 428 | 16.49 |
10:55 ET | 100 | 16.48 |
10:57 ET | 100 | 16.5 |
11:02 ET | 100 | 16.41 |
11:06 ET | 100 | 16.5 |
11:08 ET | 100 | 16.455 |
11:09 ET | 252 | 16.49 |
11:11 ET | 223 | 16.5 |
11:15 ET | 306 | 16.47 |
11:20 ET | 600 | 16.36 |
11:22 ET | 100 | 16.31 |
11:24 ET | 100 | 16.33 |
11:26 ET | 300 | 16.37 |
11:27 ET | 100 | 16.3825 |
11:31 ET | 200 | 16.41 |
11:33 ET | 100 | 16.41 |
11:36 ET | 229 | 16.47 |
11:40 ET | 100 | 16.46 |
11:44 ET | 100 | 16.41 |
11:47 ET | 200 | 16.44 |
11:51 ET | 100 | 16.405 |
11:58 ET | 700 | 16.395 |
12:02 ET | 400 | 16.35 |
12:07 ET | 343 | 16.328 |
12:12 ET | 100 | 16.32 |
12:14 ET | 400 | 16.29 |
12:18 ET | 200 | 16.33 |
12:20 ET | 100 | 16.28 |
12:21 ET | 644 | 16.27 |
12:25 ET | 100 | 16.22 |
12:32 ET | 300 | 16.22 |
12:34 ET | 897 | 16.28 |
12:36 ET | 2000 | 16.29 |
12:38 ET | 207 | 16.3 |
12:39 ET | 200 | 16.3 |
12:43 ET | 340 | 16.3 |
12:48 ET | 1182 | 16.32 |
12:52 ET | 300 | 16.28 |
12:59 ET | 511 | 16.3 |
01:01 ET | 1986 | 16.3 |
01:06 ET | 2000 | 16.295 |
01:08 ET | 889 | 16.295 |
01:12 ET | 100 | 16.295 |
01:15 ET | 3700 | 16.29 |
01:19 ET | 100 | 16.29 |
01:24 ET | 325 | 16.25 |
01:26 ET | 117 | 16.25 |
01:30 ET | 9392 | 16.27 |
01:32 ET | 700 | 16.31 |
01:33 ET | 38800 | 16.265 |
01:35 ET | 3386 | 16.22 |
01:37 ET | 893 | 16.22 |
01:44 ET | 250 | 16.2999 |
01:46 ET | 100 | 16.29 |
01:48 ET | 1000 | 16.19 |
01:50 ET | 200 | 16.225 |
02:00 ET | 200 | 16.22 |
02:02 ET | 1736 | 16.28 |
02:04 ET | 100 | 16.31 |
02:08 ET | 400 | 16.32 |
02:09 ET | 201 | 16.35 |
02:11 ET | 300 | 16.38 |
02:13 ET | 911 | 16.39 |
02:15 ET | 200 | 16.355 |
02:18 ET | 100 | 16.39 |
02:24 ET | 472 | 16.35 |
02:26 ET | 4749 | 16.47 |
02:27 ET | 3523 | 16.45 |
02:29 ET | 1000 | 16.425 |
02:33 ET | 100 | 16.5 |
02:36 ET | 3092 | 16.47 |
02:38 ET | 1642 | 16.5 |
02:40 ET | 2990 | 16.48 |
02:42 ET | 200 | 16.455 |
02:44 ET | 100 | 16.47 |
02:45 ET | 200 | 16.455 |
02:47 ET | 986 | 16.42 |
02:49 ET | 100 | 16.435 |
02:51 ET | 100 | 16.4 |
02:54 ET | 100 | 16.4 |
02:56 ET | 2500 | 16.36 |
03:07 ET | 100 | 16.365 |
03:12 ET | 200 | 16.37 |
03:16 ET | 300 | 16.33 |
03:18 ET | 900 | 16.36 |
03:20 ET | 700 | 16.335 |
03:21 ET | 600 | 16.37 |
03:25 ET | 200 | 16.4 |
03:30 ET | 440 | 16.38 |
03:32 ET | 510 | 16.38 |
03:34 ET | 3450 | 16.42 |
03:39 ET | 1585 | 16.34 |
03:41 ET | 100 | 16.325 |
03:43 ET | 200 | 16.315 |
03:45 ET | 700 | 16.35 |
03:48 ET | 28680 | 16.21 |
03:50 ET | 5600 | 16.185 |
03:52 ET | 915 | 16.17 |
03:54 ET | 1275 | 16.19 |
03:56 ET | 50831 | 16.105 |
03:57 ET | 4032 | 16.095 |
03:59 ET | 8037 | 16.19 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Celcuity Inc | 584.1M | -5.8x | --- |
Cassava Sciences Inc | 582.4M | -10.1x | --- |
Erasca Inc | 580.7M | -2.8x | --- |
PepGen Inc | 580.6M | -5.0x | --- |
Mineralys Therapeutics Inc | 604.2M | -5.5x | --- |
Arrivent Biopharma Inc | 607.9M | 0.0x | --- |
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $584.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.81 |
EPS | $-2.79 |
Book Value | $5.48 |
P/E Ratio | -5.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.